CD163 and glioblastoma: To further elucidate the molecular mechanism of M2-TAMs in tumor promotion, GEPIA was utilized to obtain the potential relationship between the survival rate of GBM patients and the expression of pan-TAM marker Iba1 (also named AIF1 in NCBI) and M2-TAM marker CD163 in TCGA database.